Canada Markets closed

Centogene N.V. (CNTG)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.9000-0.2000 (-6.45%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.1000
Bid1.2400 x 2900
Ask3.8000 x 900
Day's Range2.7000 - 3.1800
52 Week Range2.7000 - 11.9500
Avg. Volume11,463
Market Cap65.282M
Beta (5Y Monthly)-1.59
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics

    Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated diagnostic expertise with testing performed in over 650,000 individuals globallyRecommendations provide standardized clinical application guidelines for laboratories to accelerate comprehensive diagnosis and promote better health outcomesWGS increasingly popular for high-quality diagnostics, with the number of CENTOGENE WGS tests increasing doubl

  • GlobeNewswire

    CENTOGENE to Present at the H.C. Wainwright Global Investment Conference

    CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the virtual track at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022, and invites investors to participate via virtual one-on-one meetings. Please see additional details below: H.C. Wainwright Global I

  • GlobeNewswire

    CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally

    Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseasesThe global market access and expansion partnership initially established in 2015 aims to provide an efficient and timely diagnosis to patientsDiagnosis remains crucial for patients, leading them towards suitable readily available t